Pharma & Healthcare

Global IBS Treatment Market Analysis and Forecast 2026-2032

Published Dec 20, 2025

Pages 219

Report Feedback

Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.

Report Overview Facts

Report ID: 1740012702
Publisher: APO Research Inc.
Published: 2025-12-20
Updated: 2026-08-08

Research methodology

Types

IBS-D
IBS-C
IBS-M

Applications

Hospitals
Clinics
Research Laboratories

Key Companies

Takeda Pharmaceutical Company (Japan)

Nestle (Switzerland)

Novartis (Switzerland)

Pfizer (U.S.)

Synthetic Biologics (U.S.)

Synergy Pharmaceuticals (U.S.)

Sucampo Pharmaceuticals (U.S.)

Sebela Pharmaceuticals (Ireland)

RedHill Biopharma (Israel)

Protagonist Therapeutics (U.S.)

Probi (Sweden)

Lexicon Pharmaceuticals (U.S.)

LinkedIn X (Twitter)Facebook Email

Report Overview Facts

Report ID: 1740012702
Publisher: APO Research Inc.
Published: 2025-12-20
Updated: 2026-08-08

Research methodology

Types

IBS-D
IBS-C
IBS-M

Applications

Hospitals
Clinics
Research Laboratories

Key Companies

Takeda Pharmaceutical Company (Japan)

Nestle (Switzerland)

Novartis (Switzerland)

Pfizer (U.S.)

Synthetic Biologics (U.S.)

Synergy Pharmaceuticals (U.S.)

Sucampo Pharmaceuticals (U.S.)

Sebela Pharmaceuticals (Ireland)

RedHill Biopharma (Israel)

Protagonist Therapeutics (U.S.)

Probi (Sweden)

Lexicon Pharmaceuticals (U.S.)

LinkedIn X (Twitter)Facebook Email

Global IBS Treatment Market Analysis and Forecast 2026-2032

Report Feedback

Report Overview Facts

Types

Applications

Key Companies

Customer Reviews

Report Overview Facts

Types

Applications

Key Companies